Literature DB >> 33736646

Patients' and healthcare professionals' perspectives on the idiopathic pulmonary fibrosis care journey: a qualitative study.

Anouk Delameillieure1,2, Fabienne Dobbels3, Sarah Vandekerkhof2, Wim A Wuyts1,4.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) highly impacts patients on several life dimensions and challenges healthcare practices in providing high-quality care. Consequently, it is crucial to establish integrated care processes, maximizing patient value and patients' individual needs. The aim of the study was to shed light on the care trajectory based on the perspectives of patients and healthcare professionals.
METHODS: The study was conducted at a tertiary Belgian IPF centre of excellence. We conducted individual interviews with patients and healthcare professionals, guided by the Chronic Care Model (CCM) as a framework for integrated care. Thematic analysis was used to underpin data analysis.
RESULTS: Experiences were gathered of nine patients with IPF (aged 57-83 years, of which the informal caregivers were present at five interviews) and nine professionals involved in the IPF care trajectory. Our findings identified pitfalls and suggestions for improvement covering all elements of the CCM, primarily at the level of the individual patient and the care team. We covered suggestions to improve the team-based care and pro-active follow-up of patients' needs. Self-management support was highlighted as an important area and we identified possibilities, but also challenges regarding the use of patient-reported outcomes and eHealth-tools. Furthermore, the importance of continuous training for professionals and the implementation of guidelines in routine care was pointed out. Also, participants mentioned an opportunity to collaborate with community-based organizations and raised challenges regarding the overall health system. Lastly, the pertaining lack of IPF awareness and the disease burden on patients and their caregivers were covered.
CONCLUSIONS: Our research team has initiated a project aiming to optimize the current care delivery practice for IPF patients at a Belgian centre of excellence. These results will inform the further optimisation of the care program and the development of feasible supportive interventions.

Entities:  

Keywords:  Chronic Care Model; Idiopathic pulmonary fibrosis; Qualitative research; Quality improvement

Year:  2021        PMID: 33736646     DOI: 10.1186/s12890-021-01431-8

Source DB:  PubMed          Journal:  BMC Pulm Med        ISSN: 1471-2466            Impact factor:   3.317


  41 in total

1.  Idiopathic pulmonary fibrosis: increased survival with "gastroesophageal reflux therapy": fact or fallacy?

Authors:  Ganesh Raghu
Journal:  Am J Respir Crit Care Med       Date:  2011-12-15       Impact factor: 21.405

Review 2.  Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.

Authors:  John Hutchinson; Andrew Fogarty; Richard Hubbard; Tricia McKeever
Journal:  Eur Respir J       Date:  2015-05-14       Impact factor: 16.671

3.  Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium.

Authors:  C Rinciog; A Diamantopoulos; A Gentilini; B Bondue; C Dahlqvist; A Froidure; W A Wuyts; S Soulard
Journal:  Pharmacoecon Open       Date:  2020-09

Review 4.  Idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Harold R Collard; Mark G Jones
Journal:  Lancet       Date:  2017-03-30       Impact factor: 79.321

Review 5.  Prevalence and outcomes of pulmonary hypertension after percutaneous closure of atrial septal defect: a systematic review and meta-analysis.

Authors:  Selai Akseer; Eric Horlick; Varnita Vishwanath; Benjamin Hobbes; Ella Huszti; Susanna Mak; Douglas S Lee; Lusine Abrahamyan
Journal:  Eur Respir Rev       Date:  2020-12-15

6.  TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis.

Authors:  Justin M Oldham; Shwu-Fan Ma; Fernando J Martinez; Kevin J Anstrom; Ganesh Raghu; David A Schwartz; Eleanor Valenzi; Leah Witt; Cathryn Lee; Rekha Vij; Yong Huang; Mary E Strek; Imre Noth
Journal:  Am J Respir Crit Care Med       Date:  2015-12-15       Impact factor: 21.405

7.  The lived experience with idiopathic pulmonary fibrosis: a qualitative study.

Authors:  Dorthe Overgaard; Gudrun Kaldan; Kristoffer Marsaa; Thyge Lynghøj Nielsen; Saher Burhan Shaker; Ingrid Egerod
Journal:  Eur Respir J       Date:  2016-02-04       Impact factor: 16.671

8.  Patients' experiences of coping with Idiopathic Pulmonary Fibrosis and their recommendations for its clinical management.

Authors:  Sameera Senanayake; Kim Harrison; Michael Lewis; Melitta McNarry; Joanne Hudson
Journal:  PLoS One       Date:  2018-05-23       Impact factor: 3.240

9.  The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review.

Authors:  Alex Diamantopoulos; Emily Wright; Katerina Vlahopoulou; Laura Cornic; Nils Schoof; Toby M Maher
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

10.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.